Neurocrine Biosciences (NBIX) stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.
↑ XThis unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Neurocrine Biosciences stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Neurocrine Biosciences stock is building a cup without handle with a 157.98 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.
The biotech company showed 18% EPS growth in its most recent report. Sales rose 25%.
Neurocrine Biosciences stock holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX) is the top-ranked stock within the group.
YOU MAY ALSO LIKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。